HK2 and melanoma: A decrease in the expression levels of various glycolytic genes, including GLUT1, GLUT3, and HK2, lactate and ATP production was observed in a panel of BRAF(V600E) melanoma cell lines treated with the BRAF inhibitor vemurafenib as well as in samples from patients undergoing BRAF inhibitor therapy.